Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025PharmaceuticalsOpen Access

Histone Deacetylases in Neurodegenerative Diseases and Their Potential Role as Therapeutic Targets: Shedding Light on Astrocytes

View Full Paper
Ask AI
Bookmark
Share

Authors

PPPedro de Sena Murteira PinheiroLDLuan Pereira DinizLFLucas Silva Franco

Discussion

Loading...

Member takes

Overview

Review highlights the role of histone deacetylases and their inhibitors in neurodegenerative diseases, suggesting astrocytes as promising therapeutic targets.

Key Points

  • HDAC inhibitors can improve cognitive and motor functions in neurodegenerative diseases, enhancing therapeutic potential.
  • Preclinical and clinical studies indicate that HDACi reduce neuroinflammatory markers and mitigate neurodegeneration effectively.
  • Targeting astrocytes with HDAC inhibitors may promote a neuroprotective environment, complementing neuron-focused therapies.
  • Emerging evidence emphasizes the need for multi-target drugs and new therapeutic strategies in managing neurodegenerative diseases.

Cite This Study

Pinheiro et al. (2025) studied this question.

synapsesocial.com/papers/68dd89e6fe798ba2fc49805bhttps://doi.org/10.3390/ph18101471
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1HDACs in the Brain: From Chromatin Remodeling to Neurodegenerative Disease2025
  2. 2Advancing histone deacetylase 6 (HDAC6) as a promising therapeutic target for Alzheimer’s disease: from molecular insights to clinical prospects2025
  3. 3Epigenetic Regulation in Ischemic Neuroprotection: The Dual Role of HDACs and HATs in Neuroinflammation and Recovery2025
  4. 4Neuronal HDAC9: A key regulator of cognitive and synaptic aging, rescuing Alzheimer's disease-related phenotypes2025
  5. 5Unlocking cardiac health: exploring the role of class I HDACs in cardiovascular diseases2025